OR WAIT null SECS
Designers adopt value-added features, different materials, and enhanced coding technologies.
The rising complexity of clinical research protocols has necessarily expanded the CRO landscape.
A look at using best practice tech transfer methods for CGTs to increase process and analytics robustness while being scalable.
March 22, 2024
CDMO White Raven aims to reduce contamination risk and gain the capability to handle multiple product formats with the installation of Cytiva’s SA25 Aseptic Filling Workcell.
March 20, 2024
FDA's approval makes Orchard Therapeutics' Lenmeldy (atidarsagene autotemcel) the first gene therapy approved to treat pediatric metachromatic leukodystrophy in the US.
March 14, 2024
Noramco Group will be an integrated North American-based API and supply chain services provider.
In a new manufacturing pact, Chime Biologics will produce DT-7012, Domain Therapeutics' antibody candidate for treating cancer that will soon be entering Phase I studies.
March 13, 2024
The company is investing more than $2 million in its analytical testing services and adding suppository manufacturing capabilities.
March 12, 2024
The Cell Shuttle platform will manufacture cell therapies for its first clinical trials by the end of the year.
March 08, 2024
The facility producer’s new innovation hub will offer manufacturing, life sciences, and infrastructure services.
March 07, 2024
Cellares CEO Fabian Gerlinghaus shares how an automated, closed-production platform with a small footprint can dramatically impact cost savings and scalability for cell and gene therapies.
March 06, 2024
The company is expanding GMP capacities at its Frankfurt site to manufacture early clinical-phase peptide APIs.
February 28, 2024
The company is investing more than $250 million into its Bloomington, Ind. Manufacturing site.